Synovial Sarcoma - Pipeline Review, H1 2018

  • ID: 4464946
  • Report
  • 215 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CoBioRes NV
  • Epizyme Inc
  • GlaxoSmithKline Plc
  • Immune Design Corp
  • Immunocore Ltd
  • Johnson & Johnson
  • MORE
Synovial Sarcoma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H1 2018, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.

Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 9, 3 and 5 respectively. Similarly, the Universities portfolio in Phase I and IND/CTA Filed stages comprises 1 and 1 molecules, respectively.

Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CoBioRes NV
  • Epizyme Inc
  • GlaxoSmithKline Plc
  • Immune Design Corp
  • Immunocore Ltd
  • Johnson & Johnson
  • MORE
Introduction
The Publisher's Report Coverage

Synovial Sarcoma - Overview

Synovial Sarcoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Synovial Sarcoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Synovial Sarcoma - Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

CoBioRes NV

Epizyme Inc

GlaxoSmithKline Plc

Immune Design Corp

Immunocore Ltd

Johnson & Johnson

Karyopharm Therapeutics Inc

Merck & Co Inc

Millennium Pharmaceuticals Inc

Novartis AG

OncoTherapy Science Inc

Pfizer Inc

Takara Bio Inc

Synovial Sarcoma - Drug Profiles

ACXT-3102 - Drug Profile

AL-3818 - Drug Profile

axitinib - Drug Profile

Carboxyamidotriazole Orotate - Drug Profile

Cellular Immunotherapy 1 for Oncology - Drug Profile

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile

CMB-305 - Drug Profile

CUE-102 - Drug Profile

everolimus - Drug Profile

Fusion Protein to Agonize CD3 for Oncology - Drug Profile

GSK-3377794 - Drug Profile

OTSA-101 - Drug Profile

pembrolizumab - Drug Profile

quisinostat hydrochloride - Drug Profile

sapanisertib - Drug Profile

selinexor - Drug Profile

Small Molecule to Inhibit DNA and Topoisomerase II for Oncology - Drug Profile

SSTC-104 - Drug Profile

tazemetostat - Drug Profile

TBI-1301 - Drug Profile

Synovial Sarcoma - Dormant Projects

Synovial Sarcoma - Discontinued Products

Synovial Sarcoma - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Synovial Sarcoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Synovial Sarcoma - Pipeline by Advenchen Laboratories LLC, H1 2018

Synovial Sarcoma - Pipeline by CoBioRes NV, H1 2018

Synovial Sarcoma - Pipeline by Epizyme Inc, H1 2018

Synovial Sarcoma - Pipeline by GlaxoSmithKline Plc, H1 2018

Synovial Sarcoma - Pipeline by Immune Design Corp, H1 2018

Synovial Sarcoma - Pipeline by Immunocore Ltd, H1 2018

Synovial Sarcoma - Pipeline by Johnson & Johnson, H1 2018

Synovial Sarcoma - Pipeline by Karyopharm Therapeutics Inc, H1 2018

Synovial Sarcoma - Pipeline by Merck & Co Inc, H1 2018

Synovial Sarcoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Synovial Sarcoma - Pipeline by Novartis AG, H1 2018

Synovial Sarcoma - Pipeline by OncoTherapy Science Inc, H1 2018

Synovial Sarcoma - Pipeline by Pfizer Inc, H1 2018

Synovial Sarcoma - Pipeline by Takara Bio Inc, H1 2018

Synovial Sarcoma - Dormant Projects, H1 2018

Synovial Sarcoma - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Synovial Sarcoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Advenchen Laboratories LLC
  • CoBioRes NV
  • Epizyme Inc
  • GlaxoSmithKline Plc
  • Immune Design Corp
  • Immunocore Ltd
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc
  • Merck & Co Inc
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • OncoTherapy
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll